LAKE FOREST, Calif.--(BUSINESS WIRE)--ReVision Optics®, Inc. (RVO), a leader in implantable inlay technology to treat presbyopia, reported a high level of satisfaction from a group of 58 patients treated for presbyopia at the Ultralase Clinics in the United Kingdom with the Company’s proprietary Vue+® near vision inlay. Mark Wevill, M.D., MBChB, FRCSEd, FCS(SA), presented the data at the 2012 ACOS Femto and Presby Ophthalmic Solutions Cataract and Refractive Surgery Symposium (PresbyOscars) held in Cannes, France.